Clinical trial
A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus…
NCT00127192 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00127192 |
|---|---|
| Title | A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044) |
| Official title | Sitagliptin (MK0431) Late Phase II Double-Blind Dose-Response Study - Type 2 Diabetes Mellitus |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | sitagliptin phosphate, Comparator: placebo (unspecified) |
| Enrollment | 363 |
| Start date | Jul 1, 2005 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Aug 5, 2005 |
| Last update posted | Jun 15, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: